These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37460393)

  • 1. Long non-coding RNA PANDAR promoted radiation and cisplatin-induced DNA damage repair through ATR/CHK1 in NSCLC.
    Zhao S; Yu N; Wang H; Wan Z; Diao C; Chen Y; Liu T; Yang Y; Gao F; Bai C; Cao K; Cai J
    J Gene Med; 2023 Dec; 25(12):e3565. PubMed ID: 37460393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
    Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
    Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells.
    Jiang HG; Chen P; Su JY; Wu M; Qian H; Wang Y; Li J
    J Cell Physiol; 2017 Dec; 232(12):3433-3443. PubMed ID: 28075014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NPRL2 sensitizes human non-small cell lung cancer (NSCLC) cells to cisplatin treatment by regulating key components in the DNA repair pathway.
    Jayachandran G; Ueda K; Wang B; Roth JA; Ji L
    PLoS One; 2010 Aug; 5(8):e11994. PubMed ID: 20700484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like growth factor-1 attenuates cisplatin-induced gammaH2AX formation and DNA double-strand breaks repair pathway in non-small cell lung cancer.
    Jeon JH; Kim SK; Kim HJ; Chang J; Ahn CM; Chang YS
    Cancer Lett; 2008 Dec; 272(2):232-41. PubMed ID: 18762365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of KLF5 promotes cisplatin-induced cell apoptosis via regulating DNA damage checkpoint proteins in non-small cell lung cancer.
    Zhang H; Shao F; Guo W; Gao Y; He J
    Thorac Cancer; 2019 May; 10(5):1069-1077. PubMed ID: 30900384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1.
    Huang J; Lin C; Dong H; Piao Z; Jin C; Han H; Jin D
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):663-672. PubMed ID: 33030583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An increased expression of long non-coding RNA PANDAR promotes cell proliferation and inhibits cell apoptosis in pancreatic ductal adenocarcinoma.
    Jiang Y; Feng E; Sun L; Jin W; You Y; Yao Y; Xu Y
    Biomed Pharmacother; 2017 Nov; 95():685-691. PubMed ID: 28886528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin-induced PANDAR-Chemo-EVs contribute to a more aggressive and chemoresistant ovarian cancer phenotype through the SRSF9-SIRT4/SIRT6 axis.
    Wang H; Li Y; Wang Y; Shang X; Yan Z; Li S; Bao W
    J Gynecol Oncol; 2024 Mar; 35(2):e13. PubMed ID: 37921598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of RIF1 on response of non-small-cell lung cancer patients to platinum-based chemotherapy by regulating MYC signaling pathway.
    Mei Y; Liu YB; Hu DL; Zhou HH
    Int J Biol Sci; 2018; 14(13):1859-1872. PubMed ID: 30443189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
    Gao BB; Wang SX
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-inhibition of Pol η and ATR sensitizes cisplatin-resistant non-small cell lung cancer cells to cisplatin by impeding DNA damage repair.
    Li XQ; Ren J; Chen P; Chen YJ; Wu M; Wu Y; Chen K; Li J
    Acta Pharmacol Sin; 2018 Aug; 39(8):1359-1372. PubMed ID: 29849128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel circular RNA hsa_circRNA_103809/miR-377-3p/GOT1 pathway regulates cisplatin-resistance in non-small cell lung cancer (NSCLC).
    Zhu X; Han J; Lan H; Lin Q; Wang Y; Sun X
    BMC Cancer; 2020 Dec; 20(1):1190. PubMed ID: 33276753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest.
    Lundholm L; Hååg P; Zong D; Juntti T; Mörk B; Lewensohn R; Viktorsson K
    Cell Death Dis; 2013 Jan; 4(1):e478. PubMed ID: 23370278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
    Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
    PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
    Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
    Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An increase in long non-coding RNA PANDAR is associated with poor prognosis in clear cell renal cell carcinoma.
    Xu Y; Tong Y; Zhu J; Lei Z; Wan L; Zhu X; Ye F; Xie L
    BMC Cancer; 2017 May; 17(1):373. PubMed ID: 28545465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation induces NORAD expression to promote ESCC radiotherapy resistance via EEPD1/ATR/Chk1 signalling and by inhibiting pri-miR-199a1 processing and the exosomal transfer of miR-199a-5p.
    Sun Y; Wang J; Ma Y; Li J; Sun X; Zhao X; Shi X; Hu Y; Qu F; Zhang X
    J Exp Clin Cancer Res; 2021 Sep; 40(1):306. PubMed ID: 34587992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
    Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
    Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long non‑coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR‑514a‑3p/ULK1 axis in human non‑small cell lung cancer.
    Shen Q; Xu Z; Xu S
    Int J Oncol; 2020 Oct; 57(4):967-979. PubMed ID: 32945379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.